At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adynovate Special Drug Use Result Survey (Perioperative Administration)
In Brief
An observational study evaluating PEGylated Recombinant Factor VIII for Hemophilia A. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This study is about a factor VIII medicine called Adynovate (TAK-660) used during surgery for people with hemophilia A who have low blood levels of factor VIII. The aims of this study are as follows: * To check for side effects from TAK-660. * To check how well TAK-660 controls bleeding when used routinely during surgery and other invasive procedures such as tooth extractions. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants will receive infusions of TAK-660 during their hospital stay for surgery according to their clinic's standard practice. The study doctors will check for bleeds and side effects from TAK-660 from surgery until discharge.
Study Details
Timeline
Interventions
Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)